Gilead Sciences, Inc. $GILD Shares Bought by Banco Bilbao Vizcaya Argentaria S.A.

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Banco Bilbao Vizcaya Argentaria S.A. increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 564,533 shares of the biopharmaceutical company's stock after purchasing an additional 4,649 shares during the quarter. Gilead Sciences makes up 0.6% of Banco Bilbao Vizcaya Argentaria S.A.'s holdings, making the stock its 26th largest position. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Gilead Sciences were worth $63,255,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in GILD. Nissay Asset Management Corp Japan ADV lifted its position in shares of Gilead Sciences by 5.2% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after buying an additional 14,009 shares during the last quarter. Golden State Wealth Management LLC raised its stake in shares of Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after acquiring an additional 109 shares in the last quarter. Mufg Securities Americas Inc. bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $1,699,000. ASR Vermogensbeheer N.V. purchased a new stake in Gilead Sciences during the first quarter valued at approximately $11,688,000. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Gilead Sciences by 4.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company's stock valued at $32,827,000 after acquiring an additional 13,194 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the completion of the transaction, the chief financial officer owned 160,110 shares of the company's stock, valued at $18,977,838.30. The trade was a 1.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the sale, the chief executive officer owned 605,725 shares in the company, valued at $69,016,306.50. The trade was a 1.62% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 82,000 shares of company stock worth $9,339,230. 0.27% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research note on Tuesday. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday. UBS Group increased their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Finally, Morgan Stanley raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $2.59 during mid-day trading on Thursday, hitting $116.14. The stock had a trading volume of 6,062,069 shares, compared to its average volume of 6,678,418. The firm has a market cap of $144.11 billion, a PE ratio of 23.14, a PEG ratio of 0.73 and a beta of 0.33. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a 50 day moving average of $112.41 and a two-hundred day moving average of $108.90. Gilead Sciences, Inc. has a twelve month low of $75.35 and a twelve month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the prior year, the firm earned $2.01 earnings per share. Gilead Sciences's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.